Funds and ETFs Scilex Holding Company

Equities

SCLX

US80880W1062

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2024-06-14 EDT 5-day change 1st Jan Change
1.61 USD +8.05% Intraday chart for Scilex Holding Company +47.71% -21.08%

ETFs positioned on Scilex Holding Company

Name Weight AuM 1st Jan change Investor Rating
0.01% 2 M€ -.--%
0.00% 775 M€ -.--% -
Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.61 USD
Average target price
5.333 USD
Spread / Average Target
+231.26%
Consensus
  1. Stock Market
  2. Equities
  3. SCLX Stock
  4. Funds and ETFs Scilex Holding Company